TY - JOUR
T1 - Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England
T2 - A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset
AU - Pilleron, Sophie
AU - Morris, Eva J A
AU - Dodwell, David
AU - Franks, Kevin N
N1 - Funding
SP was supported by the European Union‘s Horizon 2020 Research and Innovation Programme, Belgium under the Marie Skłodowska-Curie grant agreement No 842817.
DD is supported by Cancer Research UK (grant no C8225/A21133). Funders had no involvement in the present study
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2023/9
Y1 - 2023/9
N2 - INTRODUCTION: We described the patterns of chemotherapy use and outcomes in patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC) by age in England.MATERIALS AND METHODS: In this retrospective population-based study, we included 20,716 (62% stage IV) patients with NSCLC diagnosed from 2014 to 2017 treated with chemotherapy. We used the Systemic Anti-Cancer Treatment (SACT) dataset to describe changes in treatment plan and estimated 30 and 90-day mortality rates and median, 6-, and 12-month overall survival (OS) using Kaplan Meier estimator for patients aged <75 and ≥ 75 by stage. Using flexible hazard regression models we assessed the impact of age, stage, treatment intent (stage III), and performance status on survival.RESULTS: Patients aged ≥75 years were less likely to receive two or more regimens, more likely to have their treatment modified because of comorbidities and their doses reduced compared to younger patients. However, early mortality rates and overall survival were similar across ages, apart from the oldest patients with stage III disease.DISCUSSION: This observational study demonstrates that age is associated with treatment patterns in an older population with advanced NSCLC in England. Although this reflects a pre-immunotherapy period, given the median age of NSCLC patients and increasingly older population, these results suggest older patients (>75 yrs) may benefit from more intense treatments.
AB - INTRODUCTION: We described the patterns of chemotherapy use and outcomes in patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC) by age in England.MATERIALS AND METHODS: In this retrospective population-based study, we included 20,716 (62% stage IV) patients with NSCLC diagnosed from 2014 to 2017 treated with chemotherapy. We used the Systemic Anti-Cancer Treatment (SACT) dataset to describe changes in treatment plan and estimated 30 and 90-day mortality rates and median, 6-, and 12-month overall survival (OS) using Kaplan Meier estimator for patients aged <75 and ≥ 75 by stage. Using flexible hazard regression models we assessed the impact of age, stage, treatment intent (stage III), and performance status on survival.RESULTS: Patients aged ≥75 years were less likely to receive two or more regimens, more likely to have their treatment modified because of comorbidities and their doses reduced compared to younger patients. However, early mortality rates and overall survival were similar across ages, apart from the oldest patients with stage III disease.DISCUSSION: This observational study demonstrates that age is associated with treatment patterns in an older population with advanced NSCLC in England. Although this reflects a pre-immunotherapy period, given the median age of NSCLC patients and increasingly older population, these results suggest older patients (>75 yrs) may benefit from more intense treatments.
UR - https://pubmed.ncbi.nlm.nih.gov/37421786
U2 - 10.1016/j.jgo.2023.101581
DO - 10.1016/j.jgo.2023.101581
M3 - Article
C2 - 37421786
SN - 1879-4068
VL - 14
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 7
M1 - 101581
ER -